Synapse - Works

Results (352)

Loss of function SETD2 mutations lead to resistance to DNA damaging chemotherapy in leukemia

Meeting Abstract

Kahn, J.; Mar, B.; Chu, H.; Graumann, P.; Zon, R.; Boettger, K.; Chu, S.; Armstrong, S.; Ebert, B.
Haematologica (2016)

Phase 1 trial of CUDC-907, a novel, oral dual inhibitor of HDAC and Pi3k: Updated assessment of patients with relapsed or refractory diffuse large B-cell lymphoma, including double expressor lymphoma

Meeting Abstract

Younes, A.; Berdeja, J.; Patel, M.; Kelly, K.; Flinn, I.; Gerecitano, J.; Neelapu, S.; Copeland, A.; Wang, J.; Gong, L.; more...
Haematologica (2016)

Fulltext@MSK | Save

Management of transaminase elevations associated with idelalisib

Meeting Abstract

Ghia, P.; Coutre, S.; Flinn, I. W.; Gopal, A. K.; O'Brien, S. M.; Salles, G. A.; Newcomb, T.; Waldapfel, C. C.; Ye, W.; Zelenetz, A. D.; more...
Haematologica (2016)

Fulltext@MSK | Save

A phase IB dose-escalation trial of isatuximab (SAR650984, anti-CD38 MAB) plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM): Interim results from 2 new dose cohorts

Meeting Abstract

Lendvai, N.; Vij, R.; Martin, T. G.; Baz, R.; Campana, F.; Mazuir, F.; Charpentier, E.; Benson, D. M.
Haematologica (2016)

Fulltext@MSK | Save

A phase IB study evaluating the safety and clinical activity of atezolizumab combined with obinutuzumab in patients with relapsed or refractory non-Hodgkin lymphoma

Meeting Abstract

Palomba, M. L.; Till, B. G.; Park, S. I.; Morschhauser, F.; Cartron, G.; Marks, R.; Penuel, E.; Chitra, S.; Byon, J. C. H.; Popplewell, L.
Haematologica (2016)

Fulltext@MSK | Save

High hemoglobin concentrations and risk of thrombosis: Causality or confounding?

Meeting Abstract

Rognvaldsson, S.; Lund, S. H.; Hultcrantz, M.; Eiriksdottir, G.; Harris, T. B.; Gudnason, V.; Kristinsson, S. Y.
Haematologica (2016)

Fulltext@MSK | Save

Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, Anti-CD38 Mab) in relapsed/refractory multiple myeloma (RRMM)

Meeting Abstract

Vij, R.; Martin, T.; Richter, J.; Cole, C.; Atanackovic, D.; Zonder, J.; Kaufman, J.; Mikhael, J.; Bensinger, W.; Dimopoulos, M.; more...
Haematologica (2016)

Fulltext@MSK | Save

Integrative genomics identifies the molecular basis of resistance to Azacitidine therapy in Myelodysplastic Syndromes

Meeting Abstract

Unnikrishnan, A.; Papaemmanuil, E.; Beck, D.; Verma, A.; Kumari, A.; Woll, P.; Richards, L.; Knezevic, K.; Chandrakanthan, V.; Thoms, J.; more...
Haematologica (2016)

Fulltext@MSK | Save

Safety study of crenolanib, a Type I FLT3 inhibitor, with cytarabine/daunorubicin or cytarabine/idarubicin induction and high-dose cytarabine consolidation in newly diagnosed FLT3+ AML

Meeting Abstract

Wang, E.; Stone, R.; Tallman, M.; Thompson, J.; Ontiveros, E.; Olson, G.; Galinsky, I.; Pond, B.; Uchida, A.; Urity, V.; more...
Haematologica (2016)

Fulltext@MSK | Save

Increased risk of second malignancies in patients with myeloproliferative neoplasms diagnosed in Sweden 1973-2009. A population-based cohort study of 9,379 patients

Meeting Abstract

Landtblom, A. R.; Bower, H.; Andersson, T. M. L.; Dickman, P. W.; Bjorkholm, M.; Kristinsson, S. Y.; Hultcrantz, M.
Haematologica (2016)

Fulltext@MSK | Save